KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) EBT Margin (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EBT Margin for 16 consecutive years, with 22.32% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 8212.0% to 22.32% in Q4 2025 year-over-year; TTM through Dec 2025 was 33.43%, a 2144.0% decrease, with the full-year FY2025 number at 33.43%, down 2144.0% from a year prior.
  • EBT Margin was 22.32% for Q4 2025 at Halozyme Therapeutics, down from 61.81% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 67.07% in Q2 2021 to a low of 22.32% in Q4 2025.
  • A 5-year average of 45.63% and a median of 49.96% in 2024 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: surged 5558bps in 2021, then tumbled -8212bps in 2025.
  • Halozyme Therapeutics' EBT Margin stood at 53.73% in 2021, then dropped by -27bps to 39.0% in 2022, then rose by 13bps to 43.98% in 2023, then skyrocketed by 36bps to 59.8% in 2024, then plummeted by -137bps to 22.32% in 2025.
  • Per Business Quant, the three most recent readings for HALO's EBT Margin are 22.32% (Q4 2025), 61.81% (Q3 2025), and 62.92% (Q2 2025).